The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study

Ali Duarte-García, Michael M. Pham, Cynthia Crowson, Shreyasee Amin, Kevin G. Moder, Rajiv K. Pruthi, Kenneth J Warrington, Eric L. Matteson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To estimate the annual incidence and prevalence of and frequency of mortality associated with antiphospholipid syndrome (APS). Methods: An inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. All cases met the 2006 Sydney criteria for APS (primary definition) or had a diagnosis of APS confirmed by physician consensus (secondary definition). Levels of lupus anticoagulant, IgM and IgG anticardiolipin antibodies, and anti–β2-glycoprotein I antibodies were tested in a centralized laboratory. Incidence rates were age- and sex-adjusted to the 2010 US white population. Prevalence estimates were obtained from the incidence rates, assuming that there was no increased mortality associated with APS and that migration in or out of the area was independent of disease status. Results: Among this cohort in 2000–2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified (mean age of patients 54.2 years; 55% female, 97% white). The annual incidence of APS in adults ages ≥18 years was 2.1 (95% confidence interval [95% CI] 1.4–2.8) per 100,000 population. Incidence rates were similar in both sexes. The estimated prevalence of APS was 50 (95% CI 42–58) per 100,000 population, and was similar in both sexes. Six patients (18%) had a concurrent diagnosis of systemic lupus erythematosus. The most frequent clinical manifestation was deep vein thrombosis. The overall frequency of mortality among patients with APS was not significantly different from that in the general population (standardized mortality ratio 1.61, 95% CI 0.74–3.05). Conclusion: APS occurred in ~2 persons per 100,000 population per year. The estimated prevalence was 50 per 100,000 population. Overall mortality was not notably different from that observed in the general population.

Original languageEnglish (US)
Pages (from-to)1545-1552
Number of pages8
JournalArthritis and Rheumatology
Volume71
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Antiphospholipid Syndrome
Epidemiology
Population
Mortality
Incidence
Confidence Intervals
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Venous Thrombosis
Systemic Lupus Erythematosus
Medical Records
Immunoglobulin M
Glycoproteins
Immunoglobulin G
Physicians

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Duarte-García, A., Pham, M. M., Crowson, C., Amin, S., Moder, K. G., Pruthi, R. K., ... Matteson, E. L. (2019). The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. Arthritis and Rheumatology, 71(9), 1545-1552. https://doi.org/10.1002/art.40901

The Epidemiology of Antiphospholipid Syndrome : A Population-Based Study. / Duarte-García, Ali; Pham, Michael M.; Crowson, Cynthia; Amin, Shreyasee; Moder, Kevin G.; Pruthi, Rajiv K.; Warrington, Kenneth J; Matteson, Eric L.

In: Arthritis and Rheumatology, Vol. 71, No. 9, 01.09.2019, p. 1545-1552.

Research output: Contribution to journalArticle

Duarte-García, Ali ; Pham, Michael M. ; Crowson, Cynthia ; Amin, Shreyasee ; Moder, Kevin G. ; Pruthi, Rajiv K. ; Warrington, Kenneth J ; Matteson, Eric L. / The Epidemiology of Antiphospholipid Syndrome : A Population-Based Study. In: Arthritis and Rheumatology. 2019 ; Vol. 71, No. 9. pp. 1545-1552.
@article{8840e5d720c0446c9b3de1c0c1144763,
title = "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study",
abstract = "Objective: To estimate the annual incidence and prevalence of and frequency of mortality associated with antiphospholipid syndrome (APS). Methods: An inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. All cases met the 2006 Sydney criteria for APS (primary definition) or had a diagnosis of APS confirmed by physician consensus (secondary definition). Levels of lupus anticoagulant, IgM and IgG anticardiolipin antibodies, and anti–β2-glycoprotein I antibodies were tested in a centralized laboratory. Incidence rates were age- and sex-adjusted to the 2010 US white population. Prevalence estimates were obtained from the incidence rates, assuming that there was no increased mortality associated with APS and that migration in or out of the area was independent of disease status. Results: Among this cohort in 2000–2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified (mean age of patients 54.2 years; 55{\%} female, 97{\%} white). The annual incidence of APS in adults ages ≥18 years was 2.1 (95{\%} confidence interval [95{\%} CI] 1.4–2.8) per 100,000 population. Incidence rates were similar in both sexes. The estimated prevalence of APS was 50 (95{\%} CI 42–58) per 100,000 population, and was similar in both sexes. Six patients (18{\%}) had a concurrent diagnosis of systemic lupus erythematosus. The most frequent clinical manifestation was deep vein thrombosis. The overall frequency of mortality among patients with APS was not significantly different from that in the general population (standardized mortality ratio 1.61, 95{\%} CI 0.74–3.05). Conclusion: APS occurred in ~2 persons per 100,000 population per year. The estimated prevalence was 50 per 100,000 population. Overall mortality was not notably different from that observed in the general population.",
author = "Ali Duarte-Garc{\'i}a and Pham, {Michael M.} and Cynthia Crowson and Shreyasee Amin and Moder, {Kevin G.} and Pruthi, {Rajiv K.} and Warrington, {Kenneth J} and Matteson, {Eric L.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/art.40901",
language = "English (US)",
volume = "71",
pages = "1545--1552",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - The Epidemiology of Antiphospholipid Syndrome

T2 - A Population-Based Study

AU - Duarte-García, Ali

AU - Pham, Michael M.

AU - Crowson, Cynthia

AU - Amin, Shreyasee

AU - Moder, Kevin G.

AU - Pruthi, Rajiv K.

AU - Warrington, Kenneth J

AU - Matteson, Eric L.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective: To estimate the annual incidence and prevalence of and frequency of mortality associated with antiphospholipid syndrome (APS). Methods: An inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. All cases met the 2006 Sydney criteria for APS (primary definition) or had a diagnosis of APS confirmed by physician consensus (secondary definition). Levels of lupus anticoagulant, IgM and IgG anticardiolipin antibodies, and anti–β2-glycoprotein I antibodies were tested in a centralized laboratory. Incidence rates were age- and sex-adjusted to the 2010 US white population. Prevalence estimates were obtained from the incidence rates, assuming that there was no increased mortality associated with APS and that migration in or out of the area was independent of disease status. Results: Among this cohort in 2000–2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified (mean age of patients 54.2 years; 55% female, 97% white). The annual incidence of APS in adults ages ≥18 years was 2.1 (95% confidence interval [95% CI] 1.4–2.8) per 100,000 population. Incidence rates were similar in both sexes. The estimated prevalence of APS was 50 (95% CI 42–58) per 100,000 population, and was similar in both sexes. Six patients (18%) had a concurrent diagnosis of systemic lupus erythematosus. The most frequent clinical manifestation was deep vein thrombosis. The overall frequency of mortality among patients with APS was not significantly different from that in the general population (standardized mortality ratio 1.61, 95% CI 0.74–3.05). Conclusion: APS occurred in ~2 persons per 100,000 population per year. The estimated prevalence was 50 per 100,000 population. Overall mortality was not notably different from that observed in the general population.

AB - Objective: To estimate the annual incidence and prevalence of and frequency of mortality associated with antiphospholipid syndrome (APS). Methods: An inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. All cases met the 2006 Sydney criteria for APS (primary definition) or had a diagnosis of APS confirmed by physician consensus (secondary definition). Levels of lupus anticoagulant, IgM and IgG anticardiolipin antibodies, and anti–β2-glycoprotein I antibodies were tested in a centralized laboratory. Incidence rates were age- and sex-adjusted to the 2010 US white population. Prevalence estimates were obtained from the incidence rates, assuming that there was no increased mortality associated with APS and that migration in or out of the area was independent of disease status. Results: Among this cohort in 2000–2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified (mean age of patients 54.2 years; 55% female, 97% white). The annual incidence of APS in adults ages ≥18 years was 2.1 (95% confidence interval [95% CI] 1.4–2.8) per 100,000 population. Incidence rates were similar in both sexes. The estimated prevalence of APS was 50 (95% CI 42–58) per 100,000 population, and was similar in both sexes. Six patients (18%) had a concurrent diagnosis of systemic lupus erythematosus. The most frequent clinical manifestation was deep vein thrombosis. The overall frequency of mortality among patients with APS was not significantly different from that in the general population (standardized mortality ratio 1.61, 95% CI 0.74–3.05). Conclusion: APS occurred in ~2 persons per 100,000 population per year. The estimated prevalence was 50 per 100,000 population. Overall mortality was not notably different from that observed in the general population.

UR - http://www.scopus.com/inward/record.url?scp=85069688260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069688260&partnerID=8YFLogxK

U2 - 10.1002/art.40901

DO - 10.1002/art.40901

M3 - Article

C2 - 30957430

AN - SCOPUS:85069688260

VL - 71

SP - 1545

EP - 1552

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -